Hereditary Papillary Renal Cancer

• HPRC is a rare genetic disorder leading to specific types of kidney tumors.
• It is caused by mutations in the MET proto-oncogene, passed down through families.
• Symptoms are often non-specific, making early detection challenging without genetic screening.
• Diagnosis involves imaging, biopsy, and crucial genetic testing for confirmation.
• Management focuses on surveillance and surgical intervention for tumors.

What is Hereditary Papillary Renal Cancer?

Hereditary Papillary Renal Cancer (HPRC) is a specific type of kidney cancer that runs in families, distinguishing it from sporadic (non-inherited) forms. It is characterized by the growth of tumors known as papillary renal cell carcinomas, which originate in the lining of the small tubes in the kidney. Unlike many cancers that occur randomly, HPRC arises due to inherited genetic mutations, predisposing individuals to develop these tumors, often at a younger age and frequently in both kidneys (bilateral) or as multiple tumors within one kidney (multifocal).

While kidney cancer generally accounts for about 4% of all adult cancers, hereditary forms like HPRC are considerably rarer, representing a small fraction of all renal cell carcinoma cases. According to the American Cancer Society, papillary renal cell carcinoma itself is the second most common type of kidney cancer, making up 10-15% of all kidney cancers, with hereditary forms being a distinct and less common subset of this category. This genetic predisposition necessitates a different approach to screening and management compared to sporadic kidney cancers.

Causes and Symptoms of HPRC

The primary causes of hereditary papillary renal cancer are germline mutations in the MET proto-oncogene, located on chromosome 7. This gene provides instructions for making a protein involved in cell growth and development. When mutated, the MET gene can become overactive, leading to uncontrolled cell proliferation and the formation of papillary renal cell carcinomas. This mutation is inherited in an autosomal dominant pattern, meaning only one copy of the altered gene in each cell is sufficient to increase the risk of developing the condition. Therefore, if one parent has the mutation, there is a 50% chance their child will inherit it.

The hereditary papillary renal cancer symptoms are often non-specific and may not appear until the tumors have grown to a significant size. In many cases, tumors are discovered incidentally during imaging performed for other reasons. When symptoms do occur, they can include:

• Blood in the urine (hematuria), which may be visible or microscopic.
• Pain in the side or back, often persistent and not relieved by rest.
• A palpable lump or mass in the abdomen or side.
• Unexplained weight loss.
• Fatigue and general malaise.

Due to the often subtle nature of these symptoms, individuals with a known family history of HPRC or a confirmed MET gene mutation typically undergo regular surveillance to detect tumors early, before symptoms develop.

Diagnosing Hereditary Papillary Renal Cancer

The process for hereditary papillary renal cancer diagnosis typically involves a combination of medical history, imaging studies, and crucial genetic testing. Given its hereditary nature, a detailed family history of kidney cancer is a critical first step. If HPRC is suspected, the diagnostic pathway usually includes:

Initial assessment often begins with imaging techniques to visualize the kidneys and identify any suspicious masses. Common imaging modalities include:

• Ultrasound: Often used as a first-line screening tool, especially in surveillance protocols for at-risk individuals.
• Computed Tomography (CT) scan: Provides detailed cross-sectional images of the kidneys, helping to characterize tumors, assess their size, and determine if they are multifocal or bilateral.
• Magnetic Resonance Imaging (MRI): Can offer additional detail, particularly useful for distinguishing between different types of kidney lesions and for patients who cannot undergo CT scans.

While imaging can detect tumors, a definitive diagnosis of papillary renal cell carcinoma usually requires a biopsy, where a small tissue sample is taken from the tumor and examined under a microscope. However, the hallmark of HPRC is the genetic component. Genetic testing for mutations in the MET proto-oncogene is essential to confirm the hereditary nature of the cancer. This test can be performed on a blood sample and is vital not only for diagnosing the affected individual but also for identifying other at-risk family members who may benefit from genetic counseling and early surveillance programs.